Barinthus Biotherapeutics Past Earnings Performance
Past criteria checks 0/6
Barinthus Biotherapeutics's earnings have been declining at an average annual rate of -25.6%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 8% per year.
Key information
-25.6%
Earnings growth rate
154.1%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 8.0% |
Return on equity | -36.3% |
Net Margin | -386.3% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Barinthus Biotherapeutics plc (NASDAQ:BRNS) Not Doing Enough For Some Investors As Its Shares Slump 32%
Nov 19Is Barinthus Biotherapeutics (NASDAQ:BRNS) In A Good Position To Invest In Growth?
Aug 31Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation
Apr 05We Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth
Jul 07Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality
Nov 17Vaccitech promotes Gemma Brown to CFO
Sep 20Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts
Aug 15Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 13Vaccitech GAAP EPS of $0.41, revenue of $17.06M
Aug 09Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%
May 19Vaccitech: Aiming For A Cure In Chronic Hepatitis B
Apr 03Vaccitech: The Next Big Vaccine Trade
Jun 27Vaccitech EPS misses by $0.69, beats on revenue
Jun 14Revenue & Expenses Breakdown
How Barinthus Biotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 15 | -58 | 41 | -7 |
30 Jun 24 | 0 | -64 | 28 | -3 |
31 Mar 24 | 0 | -71 | 34 | -3 |
31 Dec 23 | 1 | -73 | 40 | -3 |
30 Sep 23 | 7 | -77 | 47 | 34 |
30 Jun 23 | 13 | -55 | 35 | 20 |
31 Mar 23 | 30 | -15 | 15 | -1 |
31 Dec 22 | 45 | 5 | 6 | -1 |
30 Sep 22 | 38 | 11 | -4 | -2 |
30 Jun 22 | 32 | -1 | 8 | -4 |
31 Mar 22 | 15 | -33 | 27 | -4 |
31 Dec 21 | 0 | -51 | 25 | -4 |
30 Sep 21 | 1 | -46 | 23 | -3 |
30 Jun 21 | 4 | -41 | 23 | -4 |
31 Mar 21 | 4 | -29 | 11 | -4 |
31 Dec 20 | 5 | -18 | 10 | -3 |
31 Dec 19 | 7 | -21 | 3 | -3 |
Quality Earnings: BRNS is currently unprofitable.
Growing Profit Margin: BRNS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BRNS is unprofitable, and losses have increased over the past 5 years at a rate of 25.6% per year.
Accelerating Growth: Unable to compare BRNS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BRNS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: BRNS has a negative Return on Equity (-36.3%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 02:45 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Barinthus Biotherapeutics plc is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
James Molloy | Alliance Global Partners |
Yi Chen | H.C. Wainwright & Co. |
Matthew Harrison | Morgan Stanley |